Literature DB >> 7009123

[Transluminal dilatation of renal artery stenoses for treatment of renovascular hypertension (author's transl)].

W D Bussmann, W Fassbinder, D Rummel, S Dowinsky, P Grützmacher, A Schöneberger, E Stark, M Kaltenbach, W Schoeppe.   

Abstract

Transluminal angioplasty according to Grüntzig was performed for 10 stenoses in 7 patients with renovascular hypertension. Nine out of 10 renal artery stenoses were passable and could be dilated. Definite angiographic improvement could be shown in each case. The degree of stenosis could be decreased from 86% to 38% on average. At the narrowest point the diameter was enlarged by a factor of 3.1. The pressure gradient at the stenosis fell on average from 147 to 26 mm Hg. The maximal arterial blood pressure which was on average 254/124 mm Hg before drug treatment, and 169/97 mm Hg after high dosage antihypertensive treatment, fell to 140/84 mm Hg immediately after dilatation. Before dilatation there was a definite increase in peripheral plasma renin activity in every case which fell from 41 to 12 ng AI/ml . h. In one out of 5 patients restenosis occurred after 3 months which could again be successfully dilated. In the two younger patients blood pressure 3 to 9 months later was normal even without antihypertensives. In the older patients normal blood pressure could be maintained with mild antihypertensive treatment.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7009123     DOI: 10.1055/s-2008-1070317

Source DB:  PubMed          Journal:  Dtsch Med Wochenschr        ISSN: 0012-0472            Impact factor:   0.628


  2 in total

1.  [Transluminal dilatation and other nonsurgical catheter technics in the treatment of renovascular hypertension].

Authors:  P Grützmacher; W D Bussmann
Journal:  Klin Wochenschr       Date:  1986-09-15

2.  Angiographic control of renal artery stenoses 6 months following percutaneous transluminal angioplasty.

Authors:  H Ingrisch; T Hegele; K W Frey
Journal:  Cardiovasc Intervent Radiol       Date:  1982       Impact factor: 2.740

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.